Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation

Conditions:   Malignant Neoplasm of Breast;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Neoplasms of Uncertain or Unknown Behavior
Interventions:   Drug: Neratinib;   Drug: Everolimus;   Drug: Palbociclib;   Drug: Trametinib
Sponsors:   M.D. Anderson Cancer Center;   Pfizer;   Puma Biotechnology, Inc.
Not yet recruiting - verified February 2017

http://ift.tt/2lOor46